F S&P 500
5,249.25 +3.00 (+0.06%) F Dow Jones
39,635.00 -7.00 (-0.02%) F Nasdaq
18,279.50 +24.50 (+0.13%) E-mini Russell 2000 Index Futur
2,070.10 +2.20 (+0.11%) Petróleo
78.07 -0.19 (-0.24%) Oro
2,362.00 -13.00 (-0.55%)
electroCore, Inc. (ECOR)
electroCore, Inc.
200 Forge Way
Suite 205
Rockaway, NJ 07866
United States
973 290 0097
https://www.electrocore.com
Sector(es): Healthcare
Industria: Medical Devices
Empleados a tiempo completo: 68
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Daniel S. Goldberger | CEO & Director | 1.05M | N/D | 1959 |
| Dr. Thomas J. Errico M.D. | Founder, Independent Director & Principal Investor | 58.12k | N/D | 1952 |
| Mr. Brian M. Posner CPA, MBA. | CFO & Corporate Secretary | 599.88k | N/D | 1962 |
| Mr. Michael Romaniw | Executive Vice President of Systems & Operations | N/D | N/D | 1957 |
Descripción
electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga for the support of general health and wellbeing; and TAC-STIM for human performance. In addition, the company offers gammacore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
Gestión corporativa
La calificación ISS Governance QuickScore de electroCore, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
